Praxis Precision Medicines, Inc. (PRAX)

NMS – Real Time Price. Currency in USD

343.20

+11.39 (3.43%)

At close: May 12, 2026, 4:00 PM EDT

09.05.2026

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

08.05.2026

Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 results and pipeline updates on the company's earnings call.

07.05.2026

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026

05.05.2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on May 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 5,420 shares of its common stock to twenty-one new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

04.05.2026

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026.

14.04.2026

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout

Praxis, a top biotech stock, surged Tuesday after the FDA assigned a potential approval date for its essential tremor treatment.

14.04.2026

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 29, 2027 and is not planning to hold an advisory committee meeting.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

05.05.2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14.04.2026

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

06.04.2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of elsunersen patients - and none on placebo - had additional improvements, including sleep, motor function, muscle tone and attention No treatment-emergent or serious adverse events related to study drug reported BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A developmental and epileptic encephalopathy (DEE). “We are thrilled to see the remarkable, consistent results from EMBRAVE Part A, showing 77% reduction in monthly seizures and disease modifying improvements in children with SCN2A early-seizure onset DEE.

Praxis Precision Medicines, Inc. (PRAX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Videos

No Data

Press releases

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Videos

No Data

Press releases

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Search stocks

Praxis Precision Medicines, Inc. (PRAX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Videos

No Data

Press releases

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Videos

No Data

Press releases

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy